Navigation Links
Cancer Antigen 72-4

ProductsCancer Antigen 72-4
Company ARUP Laboratories
Item Cancer Antigen 72-4
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Breast Cancer Camera
2. Cancer Antigen 125 (Trademark of Fujirebio Diagnostic Inc.)
3. Vysis UroVysion Bladder Cancer Kit
4. Physicians Cancer Chemotherapy Drug Manual 2005
5. Pocket Guide to Colorectal Cancer Drugs and Treatment
6. Cochrane Reviews in Prostatic Diseases and Urologic Cancers
7. AFP (Liver Cancer)
8. Alpha Fetoprotein (Liver Cancer)
9. NMP22 Bladder Cancer ELISA Test Kit
10. BRAF V600E Detection of Colon Cancer (Unstable Tumors) by PCR
11. Cancer Antigen 27.29
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...s are not good for children, we have already been ...ps with wireless internet too. // Professor Lawrie...bile phone safety research, said children should k...e embedded antennas. Challis, a retired professor...
...men in two Jharkhand villages have given birth to ...d villagers has blamed the air and water pollution...f Chatro village in Giridih district, around 200 k...ith their newborns Saturday. The babies were admit...
... cancer has not just pulled her down but along wit...he illness. The cancer of the bone, brain //and br... difficult to bear the physical and mental pain of... to ease the pain. It was then the family got help...
...unds like some travel deal, except that it isn't. ...ing at wineries and feasting //at local gourmet re...untry towns of Albury and Wodonga, in Victoria, Au...ctors and their families for free- just to check o...
Other Medicine News:Health News:Women Deliver Babies With Eye Defects in Jharkhand Villages 2Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Enticing Doctors to Rural Community an Uphill Task 2
(Date:9/3/2008)...EVA, Sept. 3 /- Artelis SA and,Selexi...monoclonal antibody,production with the achievemen...er. This record level was accomplished by applying...rformance stable Selexis CHO,production cell line ...t,Selexis SA using their proprietary Selexis Genet...
(Date:9/3/2008)...iscuss Phase 3 Plans with FDA, PRINCETON, N.J., S...nnounced today that it successfully completed two ...any,s new, innovative low-dose, once-weekly,contr... internal product,code AG-200-15. The Phase 2b saf...y endpoint of ovulation suppression, cycle control...
(Date:9/3/2008)...n Repeat-Dosing Study in Subjects with ALS, RICHM...gamo,BioSciences, Inc. (Nasdaq: SGMO ) announced ...(SB-509-801) to evaluate its drug, SB-509, in subj...euron disease for which there,are limited treatmen...s an injectable formulation of a plasmid,encoding ...
(Date:9/2/2008)...swire-FirstCall/ --, - This Analysis Showed That ...ke by 34% in Patients With Atrial Fibrillation or ...hrombotic Therapy, The results of a post-hoc anal...ted today at the clinical trial update session of ...in Munich, Germany. Previous results,from the land...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Waterpipe Smoking in Colleges Could Become Public Health Problem 19380 1Waterpipe Smoking in Colleges Could Become Public Health Problem 19380 2Biomarkers Predict Heart Deaths 19375 1Biomarkers Predict Heart Deaths 19375 2Biomarkers Predict Heart Deaths 19375 3LIFE Foundation Launches Lifehappens org to Help Consumers Make Smart Insurance Buying Decisions 19372 1LIFE Foundation Launches Lifehappens org to Help Consumers Make Smart Insurance Buying Decisions 19372 2LIFE Foundation Launches Lifehappens org to Help Consumers Make Smart Insurance Buying Decisions 19372 3Iowa Resident Dies After Using Contaminated Blood Thinner 5404 1Iowa Resident Dies After Using Contaminated Blood Thinner 5404 2Iowa Resident Dies After Using Contaminated Blood Thinner 5404 3
...GTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Criti...ced the publication,of data from a pivotal Phase I...ded-release tablets in the June 2007 issue of the,...S. Food and Drug,Administration (FDA) on May 30, 2...romotion partner Dey, L.P. (DEY), expects to,begin...
...Data Presented at EULAR Confirms Efficacy with Eit..., Spain, 14 June 2007 - 7:00 am CET - New pivotal ... European Congress of,Rheumatology (EULAR) show th...d, Fc-free anti-TNF, combined with methotrexate,th...ng the signs,and symptoms of active rheumatoid art...
Other Medicine Technology:Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8